HealthDay News — Supplementation with omega-3 fatty acids is not associated with fatal or nonfatal coronary heart disease or major vascular events, according to a review published in JAMA Cardiology.
Theingi Aung, MBBS, from the University of Oxford in the United Kingdom, and colleagues conducted a meta-analysis of all large trials assessing the correlation of omega-3 fatty acid supplements with the risk of fatal and nonfatal coronary heart disease and major vascular events. Study-level data were obtained from 10 large randomized clinical trials with a total of 77,917 high-risk individuals; the trials lasted a mean of 4.4 years.
The researchers found that there was no correlation for randomization to omega-3 fatty acid supplementation with coronary heart disease death (rate ratio, 0.93; 99% CI, 0.83-1.03; P =.05), nonfatal myocardial infarction (rate ratio, 0.97; 99% CI, 0.87-1.08; P =.43), or any coronary heart disease events (rate ratio, 0.96; 95% CI, 0.9-1.01; P =.12). Randomization to omega-3 fatty acid supplementation also had no significant associations with major vascular events (rate ratio, 0.97; 95% CI, 0.93-1.1; P =.1) overall or in any subgroups.
This meta-analysis “provides no support for current recommendations for the use of such supplements in people with a history of coronary heart disease,” the authors wrote.
Disclosures: Several authors disclosed financial ties to the pharmaceutical industry.
Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: met-analysis of 10 trials involving 77917 individuals [published online January 31, 2018]. JAMA Cardiol. doi:10.1001/jamacardio.2017.5205